.webp)
retatrutide and heart Data: What Surprised Cardiologists Retatrutide heart rate: what the
Description
Lee, E., Walker, C., & Ayadi, B
TRIUMPH-4, the first Phase 3 obesity readout (Dec 2025), reported about 28.7% mean weight loss at the top dose at 76 weeks the largest figure seen in any GLP-class trial so far
MACE, Major adverse cardiovascular events
If youre looking for weight management options, there are many available already
doi: 10.1038/s41467-024-47799-z
Peptide Monthly Cost Analysis The following table summarizes the estimated monthly cost for each peptide during its active protocol period
